MORGAN STANLEY PLC/CALL/STRYKER CORP./450/0.1/21.03.25 Stock

Warrant

DE000MG0YH00

Real-time Bid/Ask 11:41:30 2024-05-20 EDT
0.28 EUR / 0.32 EUR 0.00% Intraday chart for MORGAN STANLEY PLC/CALL/STRYKER CORP./450/0.1/21.03.25
Current month-40.00%
1 month-47.37%
Date Price Change
24-05-20 0.28 -6.67%
24-05-17 0.3 0.00%
24-05-16 0.3 0.00%
24-05-15 0.3 +11.11%
24-05-14 0.27 -3.57%

Delayed Quote Börse Stuttgart

Last update May 20, 2024 at 09:54 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying STRYKER CORPORATION
Issuer Morgan Stanley
WKN MG0YH0
ISINDE000MG0YH00
Date issued 2024-03-27
Strike 450 $
Maturity 2025-03-21 (305 Days)
Parity 10 : 1
Emission price 0.79
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.95
Lowest since issue 0.26
Spread 0.04
Spread %12.50%

Company Profile

Stryker Corporation is one of the world's leaders in designing, manufacturing, and selling orthopedic equipments. Net sales break down by family of products as follows: - surgical equipments and neurotechnology products (57.5%): electric motorized surgical instruments, surgical navigation systems, endoscopy equipment, digital imaging systems, neurosurgery equipments, neurovascular devices, etc. The group also offers hospital beds, gurneys, stretchers, and emergency room equipment; - orthopedic implants (42.5%): joint prostheses, traumatology implants, micro-implants, orthopedic cement, orthobiology products, etc. The group also provides spinal implants. At the end of 2022, the group had 48 production sites worldwide. Net sales are distributed geographically as follows: the United States (73.9%), Europe/Middle East/Africa (12.7%), Asia/Pacific (10.2%) and other (3.2%).
Sector
-
More about the company

Ratings for Stryker Corporation

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Stryker Corporation

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
334.7 USD
Average target price
372.4 USD
Spread / Average Target
+11.26%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW